Press Release


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Spectrum Pharmaceuticals to Host Conference Call to Discuss Second Quarter Financial and Operating Results

August 13, 2003 at 12:00 AM EDT
Spectrum Pharmaceuticals to Host Conference Call to Discuss Second Quarter Financial and Operating ResultsWednesday August 13, 9:56 am ET

IRVINE, CA--(MARKET WIRE)--Aug 13, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC: SPPI) will hold a conference call on Monday, August 18th at 10:30 a.m. Eastern time (7:30 a.m. Pacific time) to discuss second quarter results and to update investors on recent developments and plans and objectives going forward.

Rajesh Shrotriya, M.D., Chairman, President and Chief Executive Officer; Luigi Lenaz, M.D., President, Oncology Division; and, John McManus, Vice President, Finance and Strategic Planning, will host the call.

To access the call please dial 888-348-7538 approximately ten minutes prior to the scheduled start time. A replay of the call will be available on our website at

Spectrum Pharmaceuticals' primary focus is to develop in-licensed drugs for the treatment and supportive care of cancer patients. The Company's lead drug, satraplatin, is a phase 3 oral, anti-cancer drug being co-developed with GPC Biotech AG. Elsamitrucin, a phase 2 drug, will initially target non-Hodgkin's lymphoma. Eoquin™ is being studied in the treatment of superficial bladder cancer, and may have applications as a radiation sensitizer. The Company is actively working to develop, seek approval for and oversee the marketing of generic drugs in the U.S. Spectrum also has a pipeline of pre-clinical neurological drug candidates for disorders such as attention-deficit hyperactivity disorder, schizophrenia, mild cognitive impairment and pain, which it is actively seeking to out-license or co-develop. For additional information, visit the Company's Web site at

This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.


For further information, please contact:

John McManus
Spectrum Pharmaceuticals, Inc.
(949) 788-6700, ext. 247